醛酮还原酶家族 1 成员 B10（AKR1B10）在消化系统癌症中的预后价值：一项荟萃分析。

Prognostic value of aldo-keto reductase family 1 member B10 (AKR1B10) in digestive system cancers: A meta-analysis.

机构信息

Department of Ophthalmology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi.

Department of General Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong.

出版信息

Medicine (Baltimore). 2021 Apr 9;100(14):e25454. doi: 10.1097/MD.0000000000025454.

DOI:10.1097/MD.0000000000025454

PMID:33832153

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8036041/

Abstract

BACKGROUND

Numbers of studies have reported that the expression of aldo-keto reductase family 1 member B10 (AKR1B10) is abnormal in digestive system cancers, and could be used as a prognostic biomarker. However, the results are argued. Therefore, we conduct a meta-analysis to comprehensively evaluate the prognostic value of high AKR1B10 expression for overall survival (OS), disease specific survival (DSS), and disease-free survival/recurrence-free survival (DFS/PFS) in digestive system cancers.

METHODS

Hazard ratios (HRs) with its 95% confidence intervals (CIs) were calculated to assess the prognostic value of AKR1B10 by using the random effects model. The STATA version 12.0 software were used to perform all the analyses.

RESULTS

Eleven articles including 1428 patients involved in this meta-analysis. The pooled analysis suggested that high AKR1B10 expression was not associated with OS (HR: 1.18; 95% CI: 0.69-2.00) and DFS/PFS (HR: 1.08, 95% CI: 0.67-1.76) in digestive system cancers. However, Further analysis revealed that high AKR1B10 expression indicated poor OS in oral squamous cell carcinomas (OSCC) (HR: 2.92, 95% CI: 1.86-4.58) and favorable DSS in hepatocellular carcinoma (HCC) (HR: 0.71, 95% CI: 0.52-0.97).

CONCLUSIONS

The prognostic value of high AKR1B10 expression varied in different types of digestive system cancers. Further studies exploring the prognostic role of AKR1B10 in digestive system cancers are needed.

摘要

背景

多项研究报道，醛酮还原酶家族 1 成员 B10（AKR1B10）在消化系统癌症中的表达异常，并可作为预后生物标志物。然而，结果存在争议。因此，我们进行了一项荟萃分析，以综合评估 AKR1B10 高表达对消化系统癌症总生存期（OS）、疾病特异性生存期（DSS）和无病生存期/无复发生存期（DFS/PFS）的预后价值。

方法

采用随机效应模型，通过风险比（HR）及其 95%置信区间（CI）来评估 AKR1B10 的预后价值。使用 STATA 版本 12.0 软件进行所有分析。

结果

该荟萃分析纳入了 11 项研究，共涉及 1428 例患者。汇总分析表明，AKR1B10 高表达与 OS（HR：1.18；95%CI：0.69-2.00）和 DFS/PFS（HR：1.08，95%CI：0.67-1.76）无关。然而，进一步分析显示，AKR1B10 高表达与口腔鳞状细胞癌（OSCC）的 OS 不良相关（HR：2.92，95%CI：1.86-4.58），与肝癌（HCC）的 DSS 良好相关（HR：0.71，95%CI：0.52-0.97）。